News Release

2026/8/24

RIBOMIC Announces Completion of Clinical Trial Site Establishment for the Phase 3 Clinical Trial of Umedaptanib Pegol in Achondroplasia

TOKYO, August 24, 2026 - RIBOMIC, Inc. (TYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, is conducting a Phase 3 clinical trial in Japan of umedaptanib pegol, an anti-FGF2 aptamer, in paediatric patients aged 2 to 14 years with achondroplasia (ACH).

RIBOMIC has now obtained Institutional Review Board (IRB) approval at six additional sites. As of today, the total number of clinical trial sites available for patient enrollment has reached 16, achieving the number of clinical trial sites initially planned by the Company

With the planned clinical trial framework originally planned by the Company now fully established, a key foundation for advancing patient enrollment has been completed. The Company will focus on accelerating patient enrollment and steadily advancing the trial. The completion represents an important milestone supporting the future progress of the trial.

Please see the following for a summary of the Phase 3 clinical trial in Japan.
https://jrct.mhlw.go.jp/en-latest-detail/jRCT2061260037

There is no change to the full-year earnings forecast for the fiscal year ending March 2027 due to this matter.

[About Umedaptanib Pegol]

Umedaptanib pegol is the international nonproprietary name (INN) for RBM-007. As an aptamer (nucleic acid medicine) that powerfully inhibits the function of fibroblast growth factor 2 (FGF2), it is expected to become a fundamental treatment directly targeting the pathogenesis of achondroplasia. This drug has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW) of Japan.

[About Achondroplasia]

Achondroplasia is a disease caused by a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. This mutation makes FGFR3 more easily activated, leading to excessive influx of FGF signals. This inhibits the normal development of cartilage and other tissues, resulting in short stature accompanied by limb shortening. It is a rare disease with an incidence of approximately 1 in 25,000 newborns and is designated as an intractable disease. The development of effective new drugs is urgently needed.

Please visit the RIBOMIC website for more information.
https://www.ribomic.com/eng/

Forward-Looking Statements This announcement contains forward-looking statements relating to current plans, estimates, strategies, beliefs and the future performance of the Company. These statements are based on the Company's current expectations in light of the information and assumptions currently available, and the Company does not guarantee the realization of these expectations. Actual results may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and News Release discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties. Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

Contacts for inquiries or additional information: RIBOMIC Inc.
ir.inquiry@ribomic.com